Drug Profile
Anti-CD7 monoclonal antibody-PAP conjugate
Alternative Names: Anti-CD7 pokeweed antiviral protein; Anti-CD7 pokeweed antiviral protein immunoconjugate; Anti-CD7 pokeweed antiviral protein immunotoxin; TXU pokeweed antiviral protein; TXU-PAPLatest Information Update: 06 Nov 2002
Price :
$50
*
At a glance
- Originator Wayne Hughes Institute
- Class Antineoplastics; Drug conjugates; Immunotoxins; Monoclonal antibodies
- Mechanism of Action RNA synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Acute myeloid leukaemia; HIV infections; Leukaemia; Lymphoma
Most Recent Events
- 06 Nov 2002 No development reported - Phase-I for Acute myeloid leukaemia in USA (unspecified route)
- 06 Nov 2002 No development reported - Phase-I for HIV infections treatment in USA (IV-infusion)
- 06 Nov 2002 No development reported - Phase-I for Leukaemia in USA (unspecified route)